Age-related macular degeneration: Beyond anti-angiogenesis

David L. Kent1,2

1The Vision Clinic, Circular Road, Kilkenny, Ireland; 2Institute of Ageing and Chronic Disease, Faculty of Health & Life Sciences, University of Liverpool, UK

Recently, anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration have been developed. These agents, originally developed for their anti-angiogenic mechanism of action, probably also work through an anti-permeability effect in preventing or reducing the amount of leakage from submacular neovascular tissue. Other treatment modalities include laser photocoagulation, photodynamic therapy with verteporfin, and submacular surgery. In reality, these latter treatments can be similarly categorized as anti-angiogenic because their sole aim is destroying or removing choroidal neovascularization (CNV). At the cellular level, CNV resembles stereotypical tissue repair that consists of several matricellular components in addition to neovascularization. In the retina, the clinical term CNV is a misnomer since the term may more appropriately be referred to as aberrant submacular repair. Furthermore, CNV raises a therapeutic conundrum: To complete or correct any reparative process in the body, angiogenesis becomes an essential component. Anti-angiogenic therapy, in all its guises, arrests repair and causes the hypoxic environment to persist, thus fueling pro-angiogenesis and further development of CNV as a component of aberrant repair. However, we realize that anti-vascular endothelial growth factor therapy preserves vision in patients with age-related macular degeneration, albeit temporarily and therefore, repeated treatment is needed. More importantly, however, anti-angiogenic therapy demonstrates that we can at the very least tolerate neovascular tissue beneath the macula and preserve vision in contrast to our historical approach of total vascular destruction. In this clinical scenario, it may be possible to look beyond anti-angiogenesis if our goal is facilitating submacular repair without destroying the neurosensory retina. Thus, in this situation of neovascular tolerance, it may be timely to consider treatments that facilitate vascular maturation, rather than its arrest or destruction. This would neutralize hypoxia, thus removing the stimulus that drives neovascularization and in turn the need for repeated lifelong intravitreal therapy. A pro-angiogenic approach would eliminate neovascular leakage and ultimately complete repair and preserve the neurosensory retina.

Our modern-day therapeutic approach to managing neovascular age-related macular degeneration (NVAMD) is overwhelmingly via anti-vascular endothelial growth factor (anti-VEGF) strategies [1-4]. There are at least two mechanisms in which these agents achieve therapeutic significance, namely, through their anti-angiogenic and anti-permeability effects. Although anti-angiogenesis has only recently joined our expanding lexicon in retinal therapeutics, in reality our approach to NVAMD has always been anti-angiogenic [5-14]. Therapeutic anti-angiogenesis has its foundations in the 1960s and 1970s when the excellent reverse optics of the human eye were first exploited to provide high-quality reproducible images with relatively compact fundus cameras and routine clinical fundus fluorescein angiography (FFA) arrived [15,16]. Coupled with this was the development of commercially available photocoagulators such as the ruby laser in 1960 and the Xenon arc, first developed in Essen, Germany, in the 1940s [17,18]. These three breakthrough developments of photography, angiography, and photocoagulation led for the first time to an expanding, albeit anecdotal, database of clinical evidence that supported anti-angiogenesis through vascular photocoagulation as a sight-saving therapy, observations that were initially seen in managing proliferative diabetic retinopathy (PDR). Thus, therapeutic anti-angiogenesis became a reality, and the targeted destruction, both direct and indirect, of abnormal blood vessels became the strategic goal of therapy for PDR and subsequently NVAMD. These initial clinical observations gave birth to the groundbreaking randomized control trials (RCTs) so familiar to present-day retinal specialists: the Diabetic Retinopathy Studies (DRS), the Early Treatment Diabetic Retinopathy Studies (ETDRS), and the Macular Photocoagulation Studies (MPS), which demonstrated for the first time that disease progression could be modified and sight saved [19-21]. These initial clinical observations and innovations led to the era of modern-day anti-angiogenesis.

However, technological advances rather than an appreciation of the underlying pathogenesis of disease conspired in this vascular-only approach to therapy, arguably at the expense of the “whole” picture of the underlying disease. This of course is wholly understandable as these early
retinal pioneers strove admirably to deal with these visually devastating conditions as the race began to halt sight loss and refine this vascular-only therapeutic approach. NVAMD is one such maculopathy that demonstrates that its pathology embraces more than just a vascular component. Even if we are to continue just targeting this single aspect, then strategies other than pure anti-angiogenesis can and should be considered. These first retinal RCTs also confirmed FFA as a pivotal investigative tool in our approach to these conditions and reinforced therapeutic anti-angiogenesis [22]. Historically, FFA was perhaps unique as an investigation in that it became the surrogate of chorioretinal disease rather than what it actually was: a clinical investigation such that angiographic interpretation rather than pathobiology continued to dictate our approach to treatment. Fifty years on, FFA retains a central role in the diagnosis of AMD but has largely been superseded by ocular coherence tomography (OCT) in terms of ongoing management [23]. This review describes the rationale for considering treatments other than anti-angiogenesis by highlighting our improved understanding of what actually constitutes AMD, the role of chronic inflammation in triggering aberrant repair, and why current therapies are prohypoxic and thus only propagate the condition in the long-term.

**DISCUSSION**

At the most fundamental, NVAMD appears to be an aberrant and stereotypical tissue repair response analogous to that occurring in skin, the tissue most commonly studied to define normal and abnormal healing responses [24-32]. Moreover, this assertion has been backed up in recent years with the recognition of the crucial role played by chronic inflammation in AMD [33-37]. From a tissue repair perspective, this role is not surprising. By definition, to generate any kind of inflammation, we require an injury. This is essentially the crucial step in activating a tissue repair response [31]. Ultimately, the nature of the reparative response generated depends on whether this insult is acute or chronic. In the case of acute injury, this could be a skin laceration such as a surgical incision, and the trigger for repair would appear to be the acute onset of local tissue hypoxia induced by the incision resulting from damage to blood vessels. This in turn generates acute inflammation and activation of the healing cascade leading to prompt and complete repair [31].

In the case of chronic diseases such as AMD, however, the initial insult can be insidious, persistent, and more difficult to define or identify. Where AMD is concerned, it has been suggested that it is dysregulated para-inflammation occurring in the aging eye that ultimately leads to chronic inflammation and in turn a chronic wound healing environment, which, by definition, is an injured tissue bed that does not heal [37-39]. This sequence of dysfunctional events in chronic diseases gives rise to the actual disease state. AMD, with its now recognized association with chronic inflammation, satisfies the definition of a chronic wound triggered by a combination of as yet poorly understood environmental insult(s) in genetically susceptible individuals and gives rise to the phenotype we recognize as AMD [40]. It would appear that the net result of this process, regardless of the precise sequence of events, is vascular dropout within the choriocapillaris causing hypoxia. This in turn leads to NVAMD [41-44]. However, hypoxia itself may not be the actual stimulus for neovascularization and other mechanisms may be at play [45-47]. Moreover, hypoxia may not adequately explain the clinical phenotypes of AMD characterized by geographic atrophy (GA) or CNV occurring within an area of GA. These phenotypes also tend to suggest that molecular components other than hypoxia, as advocated here, may be involved in the overall pathobiology of AMD. However, if AMD is considered from a wound healing perspective, the following hypothesis might be valid (Figure 1) [48]. Age-related hypoxia and ischemia of the outer macula including the retinal pigment epithelium (RPE) triggers oxidative stress and a secondary inflammatory response, itself part of the necessary response to generate healing. However, because the insult persists, the inflammation becomes chronic and increasingly amplified over years or even decades as the outer macula becomes even more hypoxic. We recognize this clinically by the appearance of drusen and pigment changes in the macula as the stressed retinal pigment epithelium, attempting to cope in this hostile environment, becomes increasingly dysfunctional. Eventually, the hypoxia becomes so profound that a neovascular response from the choriocapillaris is triggered, which we recognize clinically as CNV. In other words, this CNV is the expected neovascular component of the predictable stereotypical wound healing response referred to above [24]. However, because the entire process of repair has been aberrant, there is excessive recruitment of scar tissue that ultimately leads to permanent vision loss from the irreversible destruction of photoreceptors, so-called disciform scar formation [49].

Fundamentally, repair has occurred albeit with a pathological outcome. The same response occurring in the skin is necessary to close wounds to prevent or limit infection, restore function, and ultimately preserve life. Thus, where the skin is concerned, the neovascular component of repair is necessary to cause skin closure. Interference with this neovascular process in the skin such as occurs in diabetes or venous stasis generates ulcer formation; thus, healing is retarded or will not occur without intervention [50-56]. In the case of the macula, this tissue repair response is clearly
aberrant since loss of central vision ensues. However, if we at least acknowledge that the response by the body is an attempt at repair and that neovascularization or CNV is essential for this repair, then it would seem intuitive that at least one therapeutic challenge going forward is to complete repair without destruction of the outer retina and thus preserve vision. Perhaps from an evolutionary perspective, a disease containment response in the form of a disciform scar with loss of central vision is a price worth paying so that at least peripheral vision is preserved, and thus, the ability to navigate independently is maintained. Devising strategies other than anti-angiogenesis that could counteract this profibrotic state seems a reasonable goal of therapy [57]. In the first instance, and based on the assumption that this requires an adequate
blood supply, it seems reasonable to suggest that this probably requires the preservation of the neovessels (CNV). In essence, all anti-angiogenesis achieves is arrest of repair, thus further fueling the ischemic response and preserving or even enhancing the hypoxic environment that triggered AMD in the first instance (Figure 2).

Before intravitreal therapy (IVT) was developed, our clinical experience bore this out. If we revisit the Macular Photocoagulation Studies data, we note such angiographic terms as “recurrence” or “persistence” of CNV, meaning that as defined by angiographic interpretation at the 6-week follow-up post-laser treatment, the neovascularization has either initially resolved and regrown (recurrence) or never fully resolved in the first place (persistence) [14]. Neovascularization, in the context of a wound healing response, has itself occurred in response to a hypoxic deficit (remember new vessel formation is but one component of a tissue repair response), and in the case of the Macular Photocoagulation Studies, thermal photocoagulation was applied to destroy the neovascular tissue making the retina/choroid tissue even more hypoxic. In this case, it is an acute, not a chronic, insult delivered by the laser, and therefore, rapid neovascular growth or regrowth occurs, all as nature intended. In other words, a further reparative response, including neovascular tissue formation, is initiated leading to recurrence or persistence of the neovascularization we recognize clinically. In cases where this does not occur, particularly in relation to the fovea, we often note clinically and on OCT that the vision is poor because of atrophic retina secondary to the AMD or scar “expansion” [58]. Thus, there is no hypoxic deficit to reactivate a wound healing response. In addition, in lesions that are extrafoveal or juxtafoveal, we note that the recurrence almost always occurs on the foveal side of the laser photocoagulation scar, again supporting the concept of the increased metabolic demand in the fovea compared to other neurosensory retina (NSR) elements and thus where the potential hypoxic deficit is maximal [59-63]. The same can be said of photodynamic therapy (PDT) with verteporfin, a “cold” laser that photoactivates a dye that is preferentially taken up by endothelial cells in neovascular tissue [64]. The photactivated dye then causes destruction of these endothelial cells by generating reactive oxygen species [65]. However, based on our hypothesis, PDT will have generated further hypoxia and therefore generation of an expected tissue repair response that ultimately leads to reperfusion of CNV or indeed further NV growth and thus the need for retreatment [10,66].

It thus seems that our anti-angiogenic approach is counterproductive in the long-term and that perhaps our therapeutic strategy should not be so much about vascular destruction as at the very least vascular tolerance until we develop more scientifically appropriate therapies that address early symptomatic or even asymptomatic stages of non-NVAMD. Yet, almost by default, PDT and especially IVT permit a primitive form of vascular tolerance. Although our current goal might remain vascular destruction, vascular containment seems more appropriate, and this has, of course, demonstrated huge benefits in terms of visual preservation as there appears to be none or little compromise or destruction...
of the overlying NSR. However, the downside is the number of injections required per eye to sustain vision. At the time of writing, this will usually mean ongoing therapy for life. IVT has also demonstrated that vision preservation is not necessarily about new blood vessels and their destruction but instead about "leakage" from the blood vessels. In modern parlance, this leakage is the new "recurrence" and thus a clinical indicator of the need for further treatment [67]. Control the "leakage," and you preserve or improve the vision. Thus, it is more appropriate to refer to this therapy as anti-inflammatory or anti-permeability rather than anti-angiogenic, bearing in mind that VEGF has also been termed vasopermeability factor (VPF) and is a potent mediator of inflammation in wound healing. Perhaps this anti-inflammatory property is more therapeutic in relation to drying up the macula and preserving photoreceptor function [68,69]. Furthermore, and in keeping with the tissue repair theme, histologically CNV demonstrates a temporal maturation of all essential components, including vascular maturation evolving from fine capillary vessels to more stable vascular structures and may be refractory or poorly responsive to anti-angiogenic agents [70], again supporting the notion that the therapeutic effect is anti-inflammatory or anti-permeability. This of course begs the question whether we should be looking at more novel agents that are solely anti-inflammatory even in the comparatively advanced stage that is NVAMD. This would permit vascular maturation to occur as there would be no coexisting anti-angiogenic action by such an agent.

The role of aging in AMD is also important. In younger patients with CNV (myopia, trauma, and uveitis), the lesion complex tends to be smaller, scar tissue recruitment is less, and resolution of disease is more rapid, suggesting that regardless of etiology and the fact that final central vision loss can be profound, a more efficient inflammatory process and by implication the repair mechanism is at work [71-75]. In the absence of an effective therapy for non-NVAMD, the challenge in the future has to be about modifying the chronicity of the NVAMD lesion complex. Further compromise of the blood supply via anti-angiogenesis will only propagate this chronicity and promote recurrence and reparative arrest [76]. The importance of renewing or improving blood supply is seen firsthand in several systemic conditions that are managed by pro-angiogenic strategies. Bypass grafting, in coronary heart and peripheral vascular disease, carotid endarterectomies, and of course the use of stents in more recent years are all indicated for vascular pathology underpinned by chronic inflammation [77-84]. In addition, the use of exercise in promoting collateral blood vessel formation similarly highlights the importance of maintaining or enhancing blood supply in ischemia, with the exception of oncologists who understandably want to limit tumor growth by compromising the tumor’s ability to recruit a blood supply. However, even in oncology an anti-angiogenic approach may be misguided due to the promotion of even greater hypoxia and inflammation in the tumor bed and the implication that this has on overall patient prognosis and survival [85,86].

The emphasis on this single neovascular aspect of CNV has also had implications for scientific research. We have many models of NVAMD, all of them imperfect but nevertheless leading to many scientific discoveries. However, almost all of them are underpinned by the drive for more anti-angiogenic therapeutic strategies. One such model is the "laser to Bruch’s membrane" now chiefly used in the rodent though first developed in the primate [87,88]. This model is an excellent proof of principle model albeit for two different reasons. First, if we rupture Bruch’s membrane, this model demonstrates neovascular in-growth into the subretinal space, analogous to that seen in NVAMD. Second, if one wants to test a therapeutic agent to prevent or retard this in-growth, this model is also ideal. In reality, it is probably more accurate to describe this model as an excellent example of acute wound healing and what occurs when one delivers an acute laser injury to the back of the eye [24]. From an AMD and anti-angiogenic perspective, this model is probably overused, as it is not a good model of chronic disease. Furthermore, the laser is an acute insult in a young mouse (as opposed to the chronic inflammatory insult of AMD in an aging human) and generates an acute inflammatory reaction. Therefore, this milieu is ideal for repair to progress through the coordinated series of phases to wound resolution [31,76]. Extrapolating the results of a potential therapy from this acute model to the reality of a diseased and aging human retina is not ideal. However, accepting these limitations, this preliminary model may be useful for investigating other aspects of the lesion complex and their potential therapies, including inflammation, scar tissue recruitment, natural history, and end stage disease without interfering with the neovascular process. Finally, this model could also provide an initial template for studying vascular maturation in the context of NVAMD.

If IVT has demonstrated that we can tolerate CNV (at the expense of reparative arrest), then the next step perhaps is to consider treatments that may stimulate or accelerate vascular maturation vis-à-vis vascular remodeling, investment with pericytes, and deposition of basement membrane as well as the role of vasculogenesis and the use of cell therapy in this process [26,89-93]. Such vascular tolerance in combination with a promotation matrix could reduce "leakage," push repair toward completion, and ultimately preserve vision. In end stage untreated or treatment failure NVAMD, these
mature vessels can often be visualized clinically and can demonstrate vascular maturation and competence angiographically and histologically [49,94]. Retinal angiomatous proliferation (RAP) may also represent a primitive or aberrant form of attempted repair in NVAMD as the vascular component of these lesions seems to represent various states of maturation that would again satisfy the definition of repair, that is, vascularization of a pro-angiogenic matrix [95-99].

An alternative hypothesis may support the use of anti-angiogenic therapy in NVAMD but in combination with therapies that promote vascular maturation and remodeling (Figure 2). In ischemia that occurs in the heart or brain, an initial hypoxia-induced acute vascular response can lead to further tissue damage due to the vasopermeability effect of VEGF causing tissue edema [68,100]. Inhibiting this VEGF effect could be therapeutically beneficial [101]. Once over the acute phase, there is the delayed phase of tissue ischemia, where stimulation, formation, maturation, and remodeling of vascular networks should promote long-term functional improvement. The merits of such a pro-angiogenic approach could be directly applicable to not only NVAMD but also non-NVAMD when one considers the postulated association between vascular dropout within the choriocapillaris and the pathogenesis of AMD [43,44]. Growth factors such as platelet-derived growth factor (PDGF), the angiopoietins (Ang), and hepatocyte growth factor (HGF) promote these different components of vascular maturation and therefore may have a role to play in promoting tissue repair in NVAMD [102-104]. Ultimately, from a wound healing perspective, combination therapy may provide a realistic and sustained benefit in the future.

In conclusion, in the absence of any effective therapy for non-NVAMD, our current therapeutic armamentarium for CNV is directly or indirectly anti-angiogenic. This approach was originally founded on the principle that blood vessels could be imaged, identified, and then thermo-ablated with laser. Eventually, this approach of neovascular intolerance gave way, initially to PDT and more recently to IVT and the evolution of a more vascular-tolerant approach. In reality, AMD, like all acquired pathologies, is a chronic disease underpinned by chronic inflammation thus creating the permissive environment that ultimately can lead to aberrant submacular repair, scar tissue recruitment, and irreversible vision loss. What we recognize clinically as CNV is the neovascular component of this reparative response. In such a situation, IVT, although undoubtedly beneficial in terms of visual preservation, propagates the hypoxic environment leading to potential reparative arrest or even a profibrotic state; thus, repeated therapy is required. Conversely, it aptly demonstrates for the first time that clinically we can tolerate the presence of neovascular tissue in the submacular space and still preserve or improve vision. This juncture in the evolution of our current understanding of CNV raises a genuine therapeutic dilemma and begs the question whether now is the time to take the “anti” out of angiogenesis and instead advocate therapies that promote disease resolution by supporting vascular maturation and essentially what we might term proangiogenic therapy.

ACKNOWLEDGMENTS

I thank Paul Quinlan (KO-OP Media Design) for his expertise with the illustrations.

REFERENCES

1. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116:57-65.
2. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-908. [PMID: 21526923].
3. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-48. [PMID: 18222192].
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31. [PMID: 17021318].
5. Age-related macular degeneration. The Macular Photocoagulation Study. Am J Ophthalmol 1984; 98:376-7. [PMID: 6540994].
6. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986; 104:694-701. [PMID: 2423061].
7. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1990; 108:816-24. [PMID: 1693496].
8. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109:1220-31. [PMID: 1718250].
9. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study
10. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117:1329-45. [PMID: 10532441].

11. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial–VIP report no. 1. Ophthalmology 2001; 108:841-9. [PMID: 11320011].

12. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448-57. [PMID: 15824216].

13. Laser photoagulation for juxtapfoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photoagulation Study Group. Arch Ophthalmol 1994; 112:500-9. see comments [PMID: 7512335].

14. Persistent and recurrent neovascularization after laser photoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol 1994; 112:489-99. [PMID: 7512335].

15. MacLean AL, Maumenee AE. Hemangioma of the choroid. Am J Ophthalmol 1960; 50:3-11. [PMID: 1449565].

16. Novotny HR, Alvis DL. A method of photographing fluorescence in circulating blood in the human retina. Circulation 1961; 24:82-6. [PMID: 13729802].

17. Maibman T. Stimulated optical radiation in ruby. Nature 1960; 187:493-4. .

18. Meyer-Schwickerath GR. The history of photoagulation. Aust N Z J Ophthalmol 1989; 17:427-34. [PMID: 2696498].

19. Preliminary report on effects of photoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976; 81:383-96. [PMID: 944535].

20. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103:1796-806. [PMID: 2866759].

21. Fine SL. Macular photoagulation study. Arch Ophthalmol 1980; 98:832-[PMID: 6155116].

22. Chamberlin JA, Bressler NM, Bressler SB, Elman MJ, Murphy RP, Flood TP, Hawkins BS, Maguire MG, Fine SL. The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Photocoagulation Study. The Macular Photocoagulation Study Group. Ophthalmology 1989; 96:1526-34. [PMID: 2479899].
of age-related macular degeneration. Science 2005; 308:419-21. [PMID: 15761120].

36. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Brackett MD, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-9. [PMID: 15761122].

37. Forrester JV. Bowman lecture on the role of inflammation in degenerative disease of the eye. Eye (Lond) 2013; 27:340-52. [PMID: 23288138].

38. Demidova-Rice TN, Hamblin MR, Herman IM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care. Adv Skin Wound Care 2012; 25:304-14. [PMID: 22713781].

39. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res 2009; 28:348-68. [PMID: 19560552].

40. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010; 29:95-112. [PMID: 19961953].

41. Nasir MA, Sugino J, Zarbin MA. Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration. Br J Ophthalmol 1997; 81:481-9. [PMID: 9274413].

42. Sarks JP, Sarks SH, Killingsworth MC. Morphology of early choriocapillaris neovascularisation in age-related macular degeneration: correlation with activity. Eye (Lond) 1997; 11:515-22. [PMID: 9425418].

43. McLeod DS, Grebe R, Bhuuto I, Merges C, Baba T, Lutty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci 2009; 50:4982-91. [PMID: 19357355].

44. Mullins RF, Johnson MN, Faidley EA, Skeie JM, Huang J. Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; 52:1606-12. [PMID: 21398287].

45. Bilton RL, Booker GW. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur J Biochem 2003; 270:791-8. [PMID: 12603312].

46. Lee BL, Kim WH, Jung J, Cho SJ, Park JW, Kim J, Chung HY, Chang MS. Nam SY. A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis 2008; 29:44-51. [PMID: 17984117].

47. Ndubuizu OI, Tsipis CP, Li A, LaManna JC. Hypoxia-inducible factor-1 (HIF-1)-independent microvascular angiogenesis in the aged rat brain. Brain Res 2010; 1366:101-9. [PMID: 20875806].

48. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122:598-614. [PMID: 15078679].

49. Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 1993; 100:1519-35. [PMID: 7692366].

50. Acosta JB, del Barco DG, Vera DC, Savigne W, Lopez-Saura P, Guillen Nieto G, Schultz GS. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J 2008; 5:530-9. [PMID: 19006574].

51. Gary Sibbald R, Woo KY. The biology of chronic foot ulcers in persons with diabetes. Diabetes Metab Res Rev 2008; 24:Suppl 1S25-30. [PMID: 18442179].

52. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology 2005; 56:Suppl 1S1-9. [PMID: 16193221].

53. Pradhan L, Cai X, Wu S, Andersen ND, Martin M, Malek J, Guthrie P, Veves A, Logerfo FW. Gene expression of pro-inflammatory cytokines and neuropeptides in diabetic wound healing. J Surg Res 2011; 167:336-42. [PMID: 20070982].

54. Pradhan L, Nahzydk C, Andersen ND, LoGerfo FW, Veves A. Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev Mol Med 2009; 11:e2-[PMID: 19138453].

55. Raffetto JD. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res 2009; 123:Suppl 4S66-71. [PMID: 19303508].

56. Smith PD. Update on chronic-venous-insufficiency-induced inflammatory processes. Angiology 2001; 52:Suppl 1S35-42. [PMID: 11510595].

57. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, Klaassen I, Schlingemann RO. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 2012; 96:587-90. [PMID: 22289291].

58. Morgan CM, Schatz H. Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation. Ophthalmology 1989; 96:96-103. [PMID: 2919053].

59. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32:375-413. [PMID: 2457955].

60. Dastgheib K, Bressler SB, Green WR. Clinicopathologic correlation of laser lesion expansion after treatment of choroidal neovascularization. Retina 1993; 13:345-52. [PMID: 7509504].

61. Fujii GY, de Juan E Jr, Pieramici DJ, Humayun MS, Phillips S, Reynolds SM, Meña M, Schachat AP. Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol 2002; 134:69-74. [PMID: 12095810].
62. Green WR. Clinicopathologic studies of treated choroidal neovascular membranes. A review and report of two cases. Retina 1991; 11:328-56. [PMID: 1720565].

63. Rosa RH, Thomas MA, Green WR. Clinicopathologic correlation of submacular membrane reattachment with retention of good vision in a patient with age-related macular degeneration. Arch Ophthalmol 1996; 114:480-7. [PMID: 8602790].

64. Okunaka T, Eckhauser ML, Kato H, Bomaminio A, Yamamoto H, Aizawa K, Sarasua MM, Koehler KA. Correlation between photodynamic efficacy of differing porphyrins and membrane partitioning behavior. Lasers Surg Med 1992; 12:98-103. [PMID: 1535406].

65. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoactivation of a murine tumor. Cancer Res 1976; 36:2326-9. [PMID: 1277137].

66. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—report 2. Arch Ophthalmol 2001; 119:198-207. [PMID: 11176980].

67. Hörster R, Ristau T, Sadda SR, Liakopoulos S. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011; 249:645-52. [PMID: 21170547].

68. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-5. [PMID: 6823562].

69. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9. [PMID: 3537791].

70. Grossniklaus HE, Miskala PH, Green WR, Bressler SB, Hawkins BS, Toth C, Wilson DJ, Bressler NM. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. Arch Ophthalmol 2005; 123:914-21. [PMID: 16009831].

71. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91:1573-81. [PMID: 6084222].

72. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992; 12:127-33. [PMID: 1439243].

73. Keane PA, Liakopoulos S, Chang KT, Heusen FM, Onghin SC, Walsh AC, Sadda SR. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 2008; 92:1081-5. [PMID: 18586903].

74. Wood CM, Richardson J. Chorioretinal neovascular membranes complicating contusional eye injuries with indirect choroidal ruptures. Br J Ophthalmol 1990; 74:93-6. [PMID: 1690025].

75. Wyszynski RE, Grossniklaus HE, Frank KE. Indirect choroidal rupture secondary to blunt ocular trauma. A review of eight eyes. Retina 1988; 8:237-43. [PMID: 2466317].

76. Grossniklaus HE, Hutchinson AK, Capone A Jr, Woolfson J, Lambert HM. Clinicopathologic features of surgically excised choroidal neovascular membranes. Ophthalmology 1994; 101:1099-111. [PMID: 7516516].

77. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-43. [PMID: 11877368].

78. Augoustides JG, Ramakrishna H. Recent advances in the management of coronary artery disease: highlights from the literature. J Cardiothorac Vasc Anesth 2009; 23:259-65. [PMID: 19324285].

79. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995; 274:165-71. [PMID: 7596006].

80. Kakisis JD, Avgerinos ED, Antonopoulos CN, Giannakopoulos TG, Moulakakis K, Liapis CD. The European Society for Vascular Surgery guidelines for carotid intervention: an updated independent assessment and literature review. Eur J Vasc Endovasc Surg 2012; 44:238-43. [PMID: 22658616].

81. Kan P, Mokin M, Dumont TM, Snyder KV, Siddiqui AH, Levy EI, Hopkins LN. Cervical carotid artery stenosis: latest update on diagnosis and management. Curr Probl Cardiol 2012; 37:127-69. [PMID: 22391407].

82. Mas JL, Trinquart L, Leys D, Albucher JF, Rousseau H, Viguier A, Bossavy JP, Denis B, Piquet P, Garnier P, Viader V, Giroud M, Krause D, Hosseini H, Bucquevin JP, Hinzelin G, Houdart E, Henon H, Neau JP, Bracard S, Onnient Y, Padovani R, Chatellier G. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008; 7:885-92. [PMID: 18774745].

83. Green GE, Paul RS, Wallsh E, Tice DA. Coronary artery bypass grafting. Surg Forum 1968; 19:159-61. [PMID: 5718598].

84. Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation 1992; 85:1197-204. [PMID: 1371432].

85. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10:858-64. [PMID: 15235597].

86. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32. [PMID: 13103003].

87. Ryan SJ. Subretinal neovascularization. Natural history of an experimental model. Arch Ophthalmol 1982; 100:1804-9. [PMID: 6182868].

88. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, Campochiaro PA. Targeted disruption of the FGF2 gene does not prevent choroidal
neovascularization in a murine model. Am J Pathol 1998; 153:1641-6. [PMID: 9811357].

89. Chan-Ling T, Baxter L, Afzal A, Sengupta N, Caballero S, Rosinova E, Grant MB. Hematopoietic stem cells provide repair functions after laser-induced Bruch’s membrane rupture model of choroidal neovascularization. Am J Pathol 2006; 168:1031-44. [PMID: 16507916].

90. Harris JR, Brown GA, Jorgensen M, Kaushal S, Ellis EA, Grant MB, Scott EW. Bone marrow-derived cells home to and regenerate retinal pigment epithelium after injury. Invest Ophthalmol Vis Sci 2006; 47:2108-13. [PMID: 16639022].

91. Bitto A, Minutoli L, Galeano MR, Altavilla D, Polito F, Fiumara T, Calo M, Lo Cascio P, Zentilin L, Giacca M, Squadrito F. Angiopoietin-1 gene transfer improves impaired wound healing in genetically diabetic mice without increasing VEGF expression. Clin Sci (Lond) 2008; 114:707-18. [PMID: 18078386].

92. Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol 2006; 169:1167-82. [PMID: 17003476].

93. Pierce GF, Tarpley JE, Yanagihara D, Mustoe TA, Fox GM, Thomason A. Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair. Am J Pathol 1992; 140:1375-88. [PMID: 16639022].

94. Green WR, Gass JD. Senile disciform degeneration of the macula. Retinal arterialization of the fibrous plaque demonstrated clinically and histopathologically. Arch Ophthalmol 1971; 86:487-94. [PMID: 5114441].

95. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol 1992; 230:11-9. [PMID: 1547961].

96. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology 1996; 103:2042-53. [PMID: 9003338].

97. Kahn D, Meunier I, Soubrane G, Coscas G. Imaging of choriotiretinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol 1995; 113:1392-8. [PMID: 7487600].

98. Lafaut BA, Aisenbrey S, Vanden Broecke C, Bartz-Schmidt KU. Clinico-pathological correlation of deep retinal vascular anomalous complex in age related macular degeneration. Br J Ophthalmol 2000; 84:1269-74. [PMID: 11049953].

99. Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N. Retinal angiomatic proliferation in age-related macular degeneration. Retina 2001; 21:416-34. [PMID: 11642370].

100. Eriksson A, Cao R, Roy J, Tritsaris K, Wahlestedt C, Dissing S, Thyberg J, Cao Y. Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation 2003; 107:1532-8. [PMID: 12654612].

101. van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, Tumas D, Gerlai R, Williams SP, van Lookeren Campagne M, Ferrara N. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 1999; 104:1613-20. [PMID: 10587525].

102. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9:604-13. [PMID: 12669032].

103. Shyu KG, Chang H, Isner JM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. J Vasc Surg 2003; 37:636-79. [PMID: 12770612].

104. Yamamoto Y, Matsuura T, Narazaki G, Sugitani M, Tanaka K, Maeda A, Shiota G, Sato K, Yoshida A, Hisatome I. Synergistic effects of autologous cell and hepatocyte growth factor gene therapy for neovascularization in a murine model of hindlimb ischemia. J Vasc Surg 2004; 39:363-71. [PMID: 14919709].

105. Chen Z, Wang J, Wang H, Xiang L, Wang Q, Jiang H, Zhang H, Tian Q, Jia Z, Lu G. Hypoxia-induced angiogenic and pericytic responses in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2005; 46:26-33. [PMID: 15678511].

106. Chen Z, Jiang H, Wang J, Wang Q, Wang H, Xiang L, Tian Q, Lu G. Hypoxia-induced expression of proangiogenic factors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2005; 46:26-33. [PMID: 15678511].

107. Chen Z, Jiang H, Wang J, Wang Q, Wang H, Xiang L, Tian Q, Lu G. Hypoxia-induced expression of proangiogenic factors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2005; 46:26-33. [PMID: 15678511].